Medtide

Medtide Intangible Assets

The Intangible Assets of Medtide (3880.HK) as of Oct 16, 2026 is 36.02 M CNY. In the previous year, Intangible Assets was 41.09 M CNY — a change of -12.35% (lower).

Intangible Assets

36.02 MCNY

YoY

-12.35%

Last updated:

Intangible Assets of Medtide is 2024 36.02 M CNY. Intangible Assets of Medtide was 2023 41.09 M CNY. It decreases by -12.35% lower compared to the previous year.

The Medtide Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2022
47.01 M CNY
Jan 1, 2023
41.09 M CNY
Jan 1, 2024
36.02 M CNY
The Medtide Intangible Assets history
YEARIntangible AssetsYoY
36.02 MCNY-12.35%
41.09 MCNY-12.60%
47.01 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide Inc, listed on the Hong Kong Stock Exchange under ticker 3880.HK, is a life sciences company headquartered in Hangzhou, China. The company, which has 522 full-time employees, specializes in peptide-focused contract research, development, and manufacturing services. Medtide provides contract research organization (CRO) services, including peptide new chemical entity (NCE) discovery and synthesis, as well as contract development and manufacturing organization (CDMO) services covering peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The company's primary focus is on delivering active pharmaceutical ingredients (APIs) rather than finished drug products. Medtide also offers peptide drug development, production, and CMC filing support services to its clients. The firm serves both domestic and international markets, operating across multiple regions. Medtide's initial public offering (IPO) is scheduled for June 30, 2025, as indicated by its IPO date. The company's website is http://medtideinc.com, where further information about its services and operations can be found. Medtide Inc. operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry, reflecting its specialized role in the pharmaceutical and biotechnology fields. The company's business model centers on providing comprehensive solutions for peptide-based drug development and manufacturing, targeting clients seeking expertise in this niche area of pharmaceutical services. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

Intangible Assets of Medtide is 36.02 M CNY in 2024.

Intangible Assets of Medtide changed from 41.09 M CNY to 36.02 M CNY, representing a -12.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Medtide since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Medtide historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medtide

All Key Metrics — Medtide